SUMMARY One hundred and forty-one patients with rheumatoid arthritis treated with aurothiopropanol sulphonate or D-penicillamine, or both were examined for HLA antigens to investigate the genetic influence on the occurrence of different adverse reactions during therapy. All 13 patients possessing HLA-DR3 had toxic reactions. The relative risk for DR3 positives of developing skin eruptions or proteinuria was calculated to be 10*5 times and seven times respectively that of DR3 negatives. The incidence of DR7 antigen in 94 patients with toxic reactions was significantly decreased (11% compared with 28% in controls) suggesting a protective role for this antigen.
Stastny,' in 1978, established that there is an association between classical or definite rheumatoid arthritis (RA), according to the American Rheumatism Association (ARA) criteria, and the HLA-DR4 antigen. A genetic predisposition to toxic reactions to sodium aurothiomalate and penicillamine therapy was suggested by Panayi,/ in the same year. In 1980 Wooley3 showed that the development of proteinuria in patients treated with sodium aurothiomalate is associated with the presence of HLA-B8 and DR3 antigens but found no significant association between these HLA antigens and haematological complications of treatment with either drug or both drugs.
Our present study reports on 141 patients with RA and analyses the associations between HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine.
Patients and methods

PATIENTS
One hundred and forty-one Caucasian patients (39 Accepted for publication 5 March 1985. Correspondence to Dr P Perrier, Centre Regional de Transfusion Sanguine, 9-11 Rue Lionnois 54000 Nancy, France. male and 102 female) with classical or definite RA, according to the ARA criteria, with a mean age of 54-3 years (range 27-77) and living in the same country were studied. Patients were selected who had received gold salts or D-penicillamine treatment for at least six months.
The mean duration of disease when therapy was started was 7-6 years (range 7 months-27 years). Ninety-eight patients (70%) were seropositive for rheumatoid factor (RF) and had a Rose-Waaler titre > 
Results
The antigenic frequency of DR4 in these 141 RA patients was 4/5%, whereas it was 24% in the control healthy population (p<10-4). The relative risk for DR4 positives of developing RA was calculated to be 2-5 times that of DR4 negatives ( Table 1) .
As shown in Tables 2 and 3 DR3 antigen was absent in 47 patients without toxic reactions, whereas 13 out of 94 patients (13-8%) with toxic reactions carried the DR3 antigen (p<10-2).
However, this antigenic frequency was not significantly different from the DR3 frequency among 254 controls (20%).
The frequency of DR7 antigen was significantly decreased in 94 RA patients with toxic reactions (11-7%) compared with controls (28-7%, p<10-3).
The statistical analysis showed a significant association between the presence of B8 and DR3 antigens and proteinuria ( Two studies have shown an association between HLA-DR3 positivity and proteinuria5 or cutaneous reactionsl' in aurothioglucose treated patients with RA.
Two other studies9 18 have shown conflicting results with respect to correlation between proteinuria due to sodium aurothiopropanol sulphonate and DR3 antigen.
Our data indicate that RA patients carrying the DR3 antigen seem to be at an increased risk of developing proteinuria and/or mucocutaneous reactions to sodium aurothiopropanol sulphonate or D-penicillamine, or both. All 13 patients carrying the DR3 antigen had toxic reactions. This association was very marked among the patients who developed proteinuria during the treatment but without correlation with the amount of proteinuria, confirming the study of Gran et al. 6 Our data relating to thrombocytopenia do not permit a clear cut conclusion to be drawn owing to the limited number of cases available. However, other studies7 11 12 favour a correlation between aurothiomalate induced thrombocytopenia and HLA-DR3 and B8. Coblyntt and Adachi12 have postulated that gold induced thrombocytopenia is immune mediated, in association with HLA-B8, DR3, with the production of platelet associated IgG leading to peripheral platelet destruction.
In contrast, DR2 and DR7 antigens were less prevalent among RA patients with toxic reactions than among patients without toxic reactions or controls, suggesting that DR2 and DR7 antigens have a protective effect, which is in agreement with several studies.6 8 15 16 However, Panayi2 reported a significant association between DR2 and toxic reactions to sodium aurothiomalate and penicillamine. Ford17 and Dequeker18 gave several explanations for these conflicting results: bias in patient selection, too small a number of patients, different preparations of gold, different definition of the non-toxic group.
Our results confirm that DR3 positivity is related to toxicity to iold and D-penicillamine. However, Van Riel et al.°have shown that DR3 positivity is also related to favourable clinical response in 25 aurothioglucose treated patients.
All these data provide evidence that HLA typing is of considerable scientific interest in the understanding of the mechanisms of drug toxicity but fails to select RA patients for gold or D-penicillamine treatment. Therefore, periodic urine analyses, blood counts, and physical examination are the better guides to therapy. 
